When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...
KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...
According to The New England Journal of Medicine, investigators at Uppsala University Hospital implanted a product called ...
If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...
A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic ...
According to DataM Intelligence, the Cystic Fibrosis (CF) Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD ...
In an unusually blunt internal memo obtained by STAT, CBER chief Vinay Prasad shared his rationale for the agency’s sweeping ...
TipRanks on MSN
Crispr Therapeutics rumor highlighted in Betaville blog
A rumor regarding Crispr Therapeutics (CRSP) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Shares of ...
HIV treatment has entered a revolutionary new era, one where a single yearly injection can keep the virus undetectable, and ...
Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date/time: Monday, ...
A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic ...
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback